Literature DB >> 1483490

Intracolonic bioavailability of human calcitonin in man.

C Beglinger1, W Born, R Muff, J Drewe, J L Dreyfuss, A Bock, M Mackay, J A Fischer.   

Abstract

Human calcitonin (hCT) injected into the lumen of the descending colon of normal human subjects was absorbed within minutes and could be recognized intact in plasma as shown by RIA in combination with reverse-phase HPLC. The absorption was low and variable, with bioavailabilities ranging from 0.01% to 2.7% relative to intravenously administered hCT (area under the concentration-time curve). With intravenous hCT serum calcium was lowered and the fractional urinary excretion of calcium, phosphorus, sodium and chloride was significantly stimulated. With the intracolonic hCT, the fractional urinary excretions of calcium, sodium and chloride were also marginally stimulated relative to intracolonic vehicle (placebo). In conclusion, hCT is absorbed intact from the colon, but the bioavailability is low and highly variable.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1483490     DOI: 10.1007/bf02285096

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Natriuretic effect of calcitonin in man.

Authors:  O L Bijvoet; J van der Sluys Veer; H R de Vries; A T van Koppen
Journal:  N Engl J Med       Date:  1971-04-01       Impact factor: 91.245

2.  Routine assay of total urinary hydroxyproline based on resin-catalysed hydrolysis.

Authors:  B C Goverde; F J Veenkamp
Journal:  Clin Chim Acta       Date:  1972-10       Impact factor: 3.786

3.  The effect of rectal and nasal administration of salmon calcitonin in normal subjects.

Authors:  T Buclin; J P Randin; A F Jacquet; M Azria; M Attinger; F Gomez; P Burckhardt
Journal:  Calcif Tissue Int       Date:  1987-11       Impact factor: 4.333

4.  The absorption of insulin from various regions of the rat intestine.

Authors:  M Kidron; H Bar-On; E M Berry; E Ziv
Journal:  Life Sci       Date:  1982-12-20       Impact factor: 5.037

5.  Intestinal absorption of the octapeptide SMS 201-995 visualized by fluorescence derivatization.

Authors:  G Fricker; C Bruns; J Munzer; U Briner; R Albert; T Kissel; J Vonderscher
Journal:  Gastroenterology       Date:  1991-06       Impact factor: 22.682

6.  Efficacy of intranasal human calcitonin in patients with Paget's disease refractory to salmon calcitonin.

Authors:  R Muff; M A Dambacher; A Perrenoud; C Simon; J A Fischer
Journal:  Am J Med       Date:  1990-08       Impact factor: 4.965

7.  Renal effects of calcitonin and parathyroid extract in man. Studies in hypoparathyroidism.

Authors:  H G Haas; M A Dambacher; J Guncaga; T Lauffenbruger
Journal:  J Clin Invest       Date:  1971-12       Impact factor: 14.808

8.  A new approach to the oral administration of insulin and other peptide drugs.

Authors:  M Saffran; G S Kumar; C Savariar; J C Burnham; F Williams; D C Neckers
Journal:  Science       Date:  1986-09-05       Impact factor: 47.728

9.  Plasma kinetics and urinary excretion of exogenous human and salmon calcitonin in man.

Authors:  R Huwyler; W Born; E E Ohnhaus; J A Fischer
Journal:  Am J Physiol       Date:  1979-01

10.  Absorption of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in rabbits.

Authors:  S Lundin; H Vilhardt
Journal:  Acta Endocrinol (Copenh)       Date:  1986-07
View more
  2 in total

1.  Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT).

Authors:  P J Sinko; Y H Lee; V Makhey; G D Leesman; J P Sutyak; H Yu; B Perry; C L Smith; P Hu; E J Wagner; L M Falzone; L T McWhorter; J P Gilligan; W Stern
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

2.  Regional permeability of salmon calcitonin in isolated rat gastrointestinal tracts: transport mechanism using Caco-2 cell monolayer.

Authors:  Rakhi B Shah; Mansoor A Khan
Journal:  AAPS J       Date:  2004-10-21       Impact factor: 4.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.